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Summary
AIM: Between October 2015 and December 2016, 11,088
patients from 42 countries having cardiac resynchronisa-
tion therapy (CRT) devices implanted were included in the
CRT II Survey. We compared the characteristics of Swiss
CRT recipients with the overall European population.
METHODS: Demographic and procedural data from sev-
en Swiss centres recruiting all consecutive patients under-
going either de-novo CRT implantation or an upgrade to a
CRT system were collected and compared with the Euro-
pean population.
RESULTS: A total of 320 Swiss patients (24.4% female,
mean age 71.0 ± 10.2 years, 47% ischaemic cardiomy-
opathy) were enrolled, which amounts to 38% of all CRT
implantations in Switzerland during this period. Of the pa-
tients enrolled, 38% had atrial fibrillation, 27% second- or
third-degree atrioventricular block, and 68% complete left
bundle-branch block. Swiss patients had significantly less
often the classical indication of heart failure with a wide
QRS complex (40 vs 61%; odds ratio [OR] 0.44, 95% con-
fidence interval [CI] 0.35–0.55; p <0.001). Compared with
the European population, Swiss patients were significant-
ly older (71 vs 68.5 years, p <0.001), less symptomatic
from heart failure and had more chronic kidney disease.
Swiss patients significantly more often received a CRT-
pacemaker (37 vs 30%; OR 1.37; 95% CI 1.09–1.73; p =
0.007) and quadripolar left ventricular leads (69 vs 57%;
OR 1.67, 95% CI 1.32–2.13; p <0.001).
: CONCLUSION: Compared with European CRT recip-
ients, Swiss CRT patients are older, less symptomatic
and suffer more often from comorbidities. Although two
thirds of the implantations were CRT-defibrillator systems,
Swiss patients more often received CRT-pacemaker sys-
tems than their European counterparts.
Keywords: cardiac resynchronisation therapy, pacemak-
er, defibrillator, survey, heart failure, implantation, sudden
cardiac death
Introduction
The benefits of cardiac resynchronisation therapy (CRT)
on long-term clinical outcomes in symptomatic heart fail-
ure patients (New York Heart Association [NYHA] class
II–IV) with reduced left ventricular (LV) ejection fraction
(EF) and electrical dyssynchrony have been repeatedly
proven in randomised controlled trials (RCTs) [1–3]. Sur-
veys and registries supplement RCTs by providing im-
portant data on daily clinical practice [1, 3]. These data
complement results from RCTs, which tend to exclude
high-risk patients [3–5]. The European Cardiac Resyn-
chronisation Therapy (CRT) Survey was conducted in
2008, as a joint project by the Heart Failure Association
(HFA) and the European Heart Rhythm Association
(EHRA) of the European Society of Cardiology (ESC) [6].
This 6-month snapshot survey included data from 2438
CRT recipients in 13 ESC member countries. At the time, it
showed underutilisation of resynchronisation therapy and
indicated that large numbers of CRT-pacemaker (CRT-P)
or -defibrillator (CRT-D) devices were implanted outside
the guideline recommendations [6]. The design of the Eu-
ropean CRT Survey II was based on the first CRT Survey
[7]. The CRT II survey included 42 ESC member countries
and its aim was to gather real-life clinical and demographic
data on current patient selection, and implantation and fol-
low-up practice [8]. Ultimately, it provides information rel-
evant for assessing healthcare resource utilisation and the
adherence to latest guidelines on CRT implantation [7, 8].
We compared the Swiss CRT utilisation with that in the
overall European population.
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Materials and methods
The rationale and design of the CRT Survey II have been
published earlier [7]. All consecutive patients planned for
CRT-P/CRT-D device implantation, de-novo or upgrade,
in a 15-month period (October 2015 to December 2016),
were included regardless of the success of the procedure.
Data were collected prospectively using an online data-
base. A central database was created and maintained at
the data management centre at the Institut für Herzinfark-
tforschung in Ludwigshafen at the Heidelberg University,
Germany. The data management centre also performed the
analyses.
The European CRT Survey II included two internet-based
questionnaires [7]. The first was a one-time questionnaire
completed by participating centres and characterised the
facility, its catchment area, invasive procedures and device
implantations performed, cardiac facilities, types of imag-
ing equipment employed, number and speciality of im-
planting physicians and the follow-up options provided,
as well as the type and source of hospital reimbursement.
The second questionnaire was an electronic case report
form (eCRF) for each patient, which collected demograph-
ic, medical history and clinical data as well as procedural
and postprocedural details. Importantly, data from unsuc-
cessful CRT implantations were also included.
Ethics approval from the relevant Ethics Committee in
Switzerland was obtained. The study protocol complied
with the Declaration of Helsinki and Good Clinical Prac-
tice.
Statistical analysis
Continuous variables are presented as median with in-
terquartile range or mean with standard deviation, as ap-
propriate. Categorical variables are presented in absolute
values and percentages. Continuous variables were com-
pared with nonparametric Mann-Whitney U-tests and cate-
gorical variables were compared with Pearson χ2 tests. De-
scriptive statistics were calculated for the available cases.
All p-values are the results of two-tailed tests and a val-
ue of <0.05 was considered significant. Statistical analysis
was carried out using SAS statistical software, version 9.1
(Cary, North Carolina, USA).
Results
Participating centres
Seven out of 36 CRT-implanting centres in Switzerland
participated in the CRT II survey (Universitätsspital Basel,
Hôpitaux Universitaires de Genève, Universitätsspital
Zurich, Cardiocentro Lugano, Kantonsspital St. Gallen,
Stadtspital Triemli Zurich and Clinique Cecil Lausanne)
[9]. During the 15-month enrolment period (October 2015
to December 2016), out of 11,088 patients recruited by
288 centres in 42 ESC member countries participating in
the CRT II Survey, 320 patients (2.9%) were recruited in
Switzerland (table 1). This was 38% of all CRT implanta-
tions in Switzerland during this period (n = 838), according
to data from the national device registry [9].
Baseline characteristics and procedural
The patient demographics are shown in table 2, procedural
data in table 3, and postprocedural data in table 4, together
with comparisons between the Swiss and European popu-
lations. There were no procedural deaths or bleeding com-
plications. One Swiss patient died during hospitalisation
from progressive heart failure.
Differences between Swiss and European CRT recipi-
ents
Compared with European CRT recipients, Swiss patients
were older (71 vs 68.5 years, p <0.001), with a significant-
ly higher proportion of patients older than 75 years (42 vs
32%, p <0.001). In both groups women were underrepre-
sented (24 vs 24%, p = 0.975). Swiss patients significantly
less often had the classical indication of heart failure with
a wide QRS complex (40 vs 61%; odds ratio [OR] 0.44,
95% confidence interval [CI] 0.35–0.55; p <0.0001), less
often presented with complete left bundle-branch block (68
vs 75%; OR 0.7, 95% CI 0.55–0.89) and consequently dis-
played a shorter mean duration of the QRS complex (152 ±
29 vs 157 ± 27 ms, p <0.01). Conversely, they significantly
more often had underlying second or third degree atrioven-
tricular block (27 vs 19%, OR 1.6, 95% CI 1.24–2.06) with
CRT employed for expected dyssynchrony induced by a
high amount of right ventricular pacing.
Although there was no overall difference in the NYHA sta-
tus, more Swiss patients were in NYHA functional class
I (6 vs 3%; OR 1.73, 95% CI 1.07–2.82) and they were
significantly less often hospitalised for heart failure the
year before implantation (32 vs 47%; OR 0.54, 95% CI
0.42–0.68), although they had significantly higher levels
of preprocedural brain natriuretic peptide (BNP) (1422 vs
1104 pg/ml, p = 0.012). Swiss patients had a higher preva-
lence of chronic kidney disease (OR 1.58, 95% CI
Table 1: Analysis overview and participating centres in Switzerland.
Switzerland All other countries
Number of patients 320 10,768
Advanced analysis population 99.7% (319/320) 96.7% (10,411/10,768)
Number of centres 7 281
Swiss centres (no. of patients)
Universitätsspital Basel 76
Hôpitaux universitaires de Genève 71
Universitätspital Zurich 43
Kantonspital St. Gallen 41
Triemli Zurich 42
Cardiocentro Lugano 34
Clinique Cecil Lausanne 13
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Table 2: Baseline characteristics and pre-procedural data of Swiss cardiac resynchronisation therapy (CRT) population and comparison with the European population.
Switzerland Europe p-value OR (95% CI)
Demographics
Age (years) 71 ± 10 68 ± 11 <0.001
Men (%) 75.6 75.7 0.98
BMI (kg/m2) 27 ± 5 28 ± 5 <0.001
Medical history
Hypertension 69 (221/320) 64 (6741/10580) 0.05 0.66 (0.51–0.86)
Diabetes mellitus 23 (75/320) 32 (3353/10601) 0.002
Obstructive lung disease 11 (35/320) 12 (1280/10602) 0.54
Atrial fibrillation 38 (121/320) 41 (4338/10600) 0.26
Paroxysmal 37 (45/121) 35 (1503/4338)
Persistent 28 (34/121) 22 (960/4338)
Permanent 35 (42/121) 43 (1847/4338)
Chronic kidney disease (<60 ml/min) 41 (132/320) 31 (3263/10587) <0.001 1.58 (1.26–1.98)
Prior revascularisation (CABG or PCI) 43 (138/320) 39 (4107/10604) 0.11
HF hospitalisation during last year 32 (103/320) 47 (4975/10597) <0.001 0.54 (0.42–0.68)
Prior device (PPM, ICD) 33 (105/320) 28 (2954/10672) 0.043 1.28 (1.01–1.62)
Primary HF aetiology 0.34
Ischaemic 47 (149/320) 44 (4726/10633)
Non-ischaemic 49 (157/320) 50 (5296/10633)
Other 4 (14/320) 6 (611/10633)
ECG
Heart rate (beats/min) 71 ± 19 72 ± 16 0.23
Sinus rhythm 68 (218/319) 69 (7278/10517) 0.55
Atrial fibrillation 24 (77/319) 26 (2701/10517) 0.55
PR interval (ms) 193 ± 53 189 ± 50 0.39
AV block II or III 27 (86/320) 18.7 (1940/10380) <0.001 1.60 (1.24–2.06)
QRS duration (ms) 152 ± 29 157 ± 27 <0.001
QRS duration <120 ms 13 (37/285) 7 (674/9250) 1.90 (1.33–2.71)
QRS duration 120–130 ms 5 (15/285) 5 (490/9250) 0.99 (0.59–1.68)
QRS duration 130–150 ms 23 (66/285) 18 (1713/9250) 1.33 (1.00–1.75)
QRS duration 150–180 ms 40 (115/285) 47 (4371/9250) 0.76 (0.59–0.96)
QRS duration >180 ms 18 (52/285) 22 (2002/9250) 0.81 (0.60–1.10)
QRS morphology
LBBB 68 (213/312) 75 (7625/10105) 0.004 0.70 (0.55–0.89)
RBBB 6 (20/312) 7 (668/10105) 0.89 0.97 (0.61–1.53)
Other 25 (79/312) 18 (1812/10105) <0.001 1.55 (1.20–2.01)
CRT indication
Heart failure with wide QRS 40 (128/317) 61 (6422/10606) <0.001 0.44 (0.35–0.55)
HF or LV dysfunction and an indication for ICD 43 (137/317) 48 (5091/10606) 0.09
PPM indication + expected pacing dependency 32 (103/317) 22 (2391/10606) <0.001 1.65 (1.30–2.10)
Evidence of medical dyssynchrony 4 (13/317) 12 (1247/10606) <0.001 0.32 (0.18–0.56)
Clinical evaluation 0.70
NYHA I 6 (18/318) 3 (352/10530)
NYHA II 34 (108/318) 38 (3975/10530)
NYHA III 55 (174/318) 54 (5735/10530)
NYHA IV 6 (18/318) 4 (468/10530)
Echocardiography
Mean LV ejection fraction (%) 30 ± 8 28 ± 8 0.005
<35% 71 (226/320) 77 (8056/10485) 1.01 (0.80–1.27)
35–50% 27 (86/320) 21 (2242/10485) 1.44 (1.08–1.94)
>50% 2 (8/320) 2 (187/10485) 1.41 (0.69–2.89)
LV end-diastolic diameter (mm) 60 ± 9 64 ± 9 <0.001
Mitral regurgitation (%) 46 (136/297) 46 (4508/9703) <0.001
Mild 16 (49/297) 27 (2597/9703) 0.97 (0.77–1.23)
Moderate 9 (26/297) 7 (664/9703) 0.54 (0.40–0.74)
Severe 29 (86/297) 20 (1934/9703) 1.31 (0.87–1.97)
Laboratory results
BNP (pg/ml) 1422 ± 2038 1104 ± 1973 0.012
NT-pro-BNP (pg/ml) 7163 ± 11993 5055 ± 8010 0.14
Haemoglobin (g/l) 132 ± 18 133 ± 18 0.32
Creatinine (μmol/l) 121 ± 68 113 ± 65 0.032
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BMI = body mass index; BNP = brain-type natriuretic peptide; CABG = coronary artery bypass grafting; HF = heart failure; ICD = implantable cardioverter-defibrillator; LBBB
= left bundle-branch block; LV = left ventricle; NT-pro-BNP = N-terminal prohormone of brain natriuretic peptide; PCI = percutaneous coronary intervention; PPM = permanent
pacemaker; RBBB = right bundle-branch block Values are % (n) for categorical and mean ± standard deviation or median (interquartile range) for continuous variables.
1.26–1.98; p <0.001) and previously implanted devices
(OR 1.28, 95% CI 1.01–1.62; p = 0.043).
In Switzerland, CRT-D systems were more often implanted
than CRT-P systems (63 vs 37%). Compared with the Eu-
ropean population, however, Swiss patients received fewer
CRT-D devices (63 vs 70%, p = 0.007). This may be ex-
plained by the older age of the patients and the fact that the
procedure was done significantly more often by an elec-
trophysiologist (OR 2.84, 95% CI 1.95–4.12; p <0.001). In
Switzerland, the quadripolar left ventricular lead was used
more often (OR 1.67, 95% CI 1.32–2.13; p <0.001), re-
flecting unhindered access to modern technology.
The overall complication rate was 4% and not different
from the European average. Postprocedural QRS duration
was not different nor was the incidence of major adverse
events. Total length of hospital stay was lower in Swiss
hospitals (5.5 vs 6.3 days, p <0.001). There was a statis-
tically significant difference between the groups regarding
the discharge medication therapy, programming of the de-
vice and follow-up planning.
Discussion
The most important findings in this registry study compar-
ing Swiss CRT recipients with their European counterparts
is that Swiss patients were older, had fewer heart failure
hospitalisations in the year before implantation and sig-
nificantly less often had the “classical” CRT indication of
symptomatic heart failure in the presence of a wide left
bundle-branch block. Although the reimbursement system
in Switzerland allows for easy access to all available tech-
nologies, significantly fewer Swiss patients received the
more expensive CRT defibrillator (CRT-D) system than in
the rest of Europe. Nonetheless, CRT-D systems still ac-
count for two thirds of all CRT implants in Switzerland.
Table 3: Procedural data of Swiss cardiac resynchronisation therapy (CRT) population and comparison with the European practice.
Switzerland Europe p-value OR (95% CI)
Elective procedure 84 (268/320) 77 (8190/10678) 0.003 1.56 (1.16–2.11)
Location of procedure 0.22
EP/Catheterisation lab. 83 (266/320) 89 (9354/10439)
Operating room 5 (16/320) 10 (1068/10439)
Other 12 (38/320) 0.2 (17/10439)
Operator <0.001
Electrophysiologist 90 (288/319) 77 (8014/10460) 2.84 (1.95–4.12)
Heart failure physician 0 (0/319) 5 (541/10460) /
Invasive cardiologist 8 (26/319) 12 (1304/10460) 0.62 (0.42–0.93)
Surgeon 2 (5/319) 4 (459/10460) 0.35 (0.14–0.84)
Duration of procedure (min) 110 (82, 136) 90 (65, 120) <0.001
Fluoroscopy time (min) 16 (10, 25) 14 (8, 22) <0.001
Successful attempt of implantation 98.8 97.2 0.09
RV lead position 0.019
Apex 67 (211/313) 61 (6069/9940) 1.32 (1.04–1.68)
Septum 31 (98/313) 37 (3635/9940) 0.79 (0.62–1.01)
RVOT 1 (4/313) 2 (236/9940) 0.53 (0.20–1.44)
LV lead position <0.001
Anterior 2 (8/317) 4 (439/9983) 0.56 (0.28–1.14)
Lateral 78 (249/317) 84 (8416/9983) 0.68 (0.52–0.90)
Posterior 19 (60/317) 11 (1128/9983) 1.83 (1.37–2.44)
Epicardial 14 (44/319) 9 (923/10214) 1.61 (1.16–2.23)
LV lead type <0.001
Unipolar 0 (0/319) 0.7 (77/10282)
Bipolar 31 (100/319) 43 (4378/10282) 0.62 (0.48–0.78)
Multipolar 69 (219/319) 57 (5827/10282) 1.67 (1.32–2.13)
Coronary venogram performed 93 (298/319) 91 (9338/10210) 0.22
Venogram performed with occlusion 61 (183/298) 47 (4303/9224) <0.001 1.82 (1.44–2.31)
Periprocedural complications 4 (13/320) 6 (611/10768) 0.21
Bleeding 0 (0/320) 1 (108/10768) 0.07
Pocket haematoma 0 (0/320) 0.8 (85/10768) 0.11
Pneumothorax 2 (7/320) 1 (105/10768) 0.033 2.27 (1.05–4.92)
Pericardial tamponade 0.3 (1/320) 0.3 (27/10768) 0.56
Coronary sinus dissection 0.3 (1/320) 2.0 (213/10768) 0.023 0.16 (0.02–1.11)
Type of the device 0.007
CRT-P 37 (118/318) 30 (3138/10451) 1.37 (1.09–1.73)
CRT-D 63 (200/318) 70 (7313/10451) 0.73 (0.58–0.92)
CRT-P = cardiac resynchronisation therapy pacemaker system; ; CRT-D = cardiac resynchronisation therapy cardioverter-defibrillator system; EP = electrophysiology; LV = left
ventricle; RV = right ventricle, RVOT = RV outflow tract Values are % (n) for categorical and mean ± standard deviation or median (interquartile range) for continuous variables
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The higher prevalence of CRT pacemaker (CRT-P) systems
may in part be explained by the fact that Swiss patients
were older and that more procedures were done by electro-
physiologists with potentially more detailed knowledge of
current risk stratification for sudden cardiac death [10–13].
On the other hand, it may also reflect a different attitude of
the patient population to the mode of death. Swiss patients
were less often hospitalised for heart failure before CRT
implantation, although they had higher levels of preproce-
dural BNP. Better access to ambulatory healthcare services
than in other countries may be the reason for that.
After the type of CRT system was chosen, Swiss patients
received the latest technology with a higher proportion of
quadripolar left ventricular leads than the European popu-
lation. Furthermore, although our population had the same
overall incidence of comorbidities, they had a higher
prevalence of chronic kidney disease, a risk factor repeat-
edly identified as hampering the effectiveness of im-
plantable cardioverter-defibrillator (ICD) therapy and
which is not improved by CRT [14, 15]. As in other CRT
and ICD trials and registries, only 25% of the recipients
were women, reflecting the fact that women are undertreat-
ed in the field of cardiovascular diseases [1, 8, 16–18].
The “classical” class I indication of symptomatic heart fail-
ure and a wide left bundle-branch block was less often the
indication for implantation in Switzerland. Relatively more
patients received an upgrade or a de-novo CRT system be-
cause they had the indication for pacing with or without
defibrillation therapy, with an expected or actual high per-
centage of ventricular pacing (e.g., in the presence of atri-
oventricular block II or III). Consequently, the Swiss group
had a greater share of patients with preprocedural QRS du-
ration <120 ms and NYHA class I. However, most patients
had symptomatic heart failure as an indication for CRT im-
plantation, displayed a left bundle-branch block morpholo-
gy on the 12-lead ECG, had a LVEF <35% and very high
Table 4: Postprocedural data of Swiss cardiac resynchronisation therapy (CRT) population and comparison with the European average.
Switzerland Europe p-value OR (95% CI)
Hospital mortality 0.3 (1/320) 0.4 (44/10525) 0.79
Device related complications 4 (13/320) 4.8 (515/10768) 0.55
Lead displacement 2 (8/320) 1.7 (180/10510) 0.29
RV 37 (3/8) 31 (52/169) 0.68
LV 37 (3/8) 53 (90/169) 0.38
Atrial 37 (3/8) 18 (31/169) 0.18
Lead malfunction 0 (0/320) 0.2 (23/10510) 0.40
Phrenic nerve stimulation 0.6 (2/320) 1.2 (121/10510) 0.38
Infection 0.6 (2/320) 0.6 (58/10496) 0.86
Stroke 0 (0/320) 0.6 (58/10496) 0.67
Worsening of HF 0.6 (2/320) 0.7 (76/10496) 0.84
Arrhythmias 0.9 (3/320) 1.2 (125/10496) 0.68
Total length of hospital stay 2 (2, 5) 3 (2, 7) <0.001
Paced QRS duration (sec) 138 ± 26 138 ± 24 0.77
Medical therapy at discharge
Diuretic 70 (223/318) 81 (8398/10317) <0.001 0.54 (0.42–0.69)
ACE inhibitor / ARB 87 (277/319) 86 (8886/10284) 0.83
Aldosterone antagonist 48 (153/319) 64 (6529/10254) <0.001 0.53 (0.42–0.66)
Beta-blocker 85 (272/319) 89 (9200/10329) 0.032 0.71 (0.52–0.97)
Digoxin 5 (17/319) 11 (1083/10225) 0.002 0.48 (0.29–0.78)
Calcium channel blocker 7 (23/317) 9 (923/10214) 0.27
Amiodarone 20 (62/317) 17 (1763/10230) 0.28
Ivabradine 0.6 (2/319) 6 (591/10224) <0.001 0.10 (0.03–0.41)
Other antiarrhythmic agent 4 (12/318) 2 (169/10213)
Oral anticoagulation 43 (136/319) 47 (4792/10258) 0.15 0.85 (0.68–1.06)
Vitamin K antagonist 59 (80/136) 71 (3383/4792) 0.003 0.59 (0.42–0.84)
Dabigatran 3 (4/136) 7 (323/4792) 0.08 0.42 (0.15–1.14)
Rivaroxaban 29 (40/136) 12 (571/4792) <0.001 3.08 (2.11–4.50)
Apixaban 6 (8/136) 10 (501/4792) 0.08 0.54 (0.26–1.10)
Edoxaban 3 (4/136) 0.3 (14/4792) <0.001 10.34 (3.36–31.84)
Platelet inhibitor 51 (162/320) 43 (4684/10768) 0.011 1.33 (1.07–1.66)
ASA 48 (152/319) 41 (4205/10228) 0.019 1.30 (1.04–1.63)
Clopidogrel 11 (35/319) 12 (1269/10228) 0.44
Ticagrelor 3 (8/319) 1 (128/10228) 0.051
Dual antiplatelet therapy 11 (34/319) 9 (947/10228) 0.39
OAC plus P2Y12 inhibitor 3 (10/319) 4 (430/10301) 0.36
Triple therapy 1 (4/319) 2 (214/10302) 0.31
Device follow-up planned
At implanting centre 68 (219/320) 87 (9126/10498) <0.001 0.33 (0.26–0.42)
Other hospital 10 (33/320) 8 (840/10498) 0.14
Private cardiologists 22 (71/320) 5 (498/10498) <0.001 5.73 (4.33–7.57)
ACE = angiotensin converting-enzyme; ARB = angiotensin-receptor blocker; ASA = acetylsalicylic acid; LV = left ventricle; OAC = oral anticoagulation; RV = right ventricle Values
are % (n) for categorical and mean ± standard deviation or median (interquartile range) for continuous variables.
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mean NT-pro BNP, which also means high adherence to
guideline recommendations by physicians [19].
Electrocardiographically, the average QRS duration de-
creased significantly with biventricular pacing, which is
expected and a predictor of good clinical response [1–3].
The reported perioperative complication rates were low,
which is in line with the fact that most of the participating
Swiss centres are high-volume centres [9, 16, 17]. The
Swiss group had no relevant bleeding complications, de-
spite the fact that almost 80% of patients took either oral
anticoagulation, antiplatelet therapy, or even both. This
could be explained by high adherence to new recommen-
dations on antithrombotic dual and triple therapy, as well
as by the experience of the recruiting centres [19–22].
In conclusion, when compared with other European coun-
tries, Swiss CRT recipients were older, less symptomatic,
received more device upgrades, had a higher incidence
of chronic kidney disease and more frequently received
quadripolar left ventricular leads. At the same time, the
percentage of CRT-D implantations was lower than in the
overall European population. Our data indicate that, de-
spite almost free access to modern technology, Swiss pa-
tients and physicians more often use the less expensive
CRT-pacemaker system with the primary goal of sympto-
matic relieve from heart failure when compared with their
European counterparts. The data from Swiss patients par-
ticipating in the European CRT Survey II provide impor-
tant information for physicians, patients and health econ-
omists and demonstrate significant differences between
Swiss and European patients in some aspects of the appli-
cation of CRT.
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